Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Other Non Operating Income (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Other Non Operating Income for 6 consecutive years, with $18.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income rose 11.9% year-over-year to $18.6 million, compared with a TTM value of -$2.0 million through Sep 2025, up 47.71%, and an annual FY2023 reading of -$2.8 million, down 131.97% over the prior year.
  • Other Non Operating Income was $18.6 million for Q4 2025 at Xeris Biopharma Holdings, up from -$6.1 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $18.6 million in Q4 2025 and bottomed at -$7.6 million in Q3 2023.
  • Average Other Non Operating Income over 5 years is -$1.4 million, with a median of -$4.4 million recorded in 2024.
  • The sharpest move saw Other Non Operating Income tumbled 340.28% in 2022, then skyrocketed 40.35% in 2023.
  • Year by year, Other Non Operating Income stood at -$2.5 million in 2021, then crashed by 34.58% to -$3.4 million in 2022, then soared by 479.71% to $12.9 million in 2023, then rose by 29.47% to $16.7 million in 2024, then grew by 11.9% to $18.6 million in 2025.
  • Business Quant data shows Other Non Operating Income for XERS at $18.6 million in Q4 2025, -$6.1 million in Q3 2025, and -$6.4 million in Q2 2025.